Princeton Global Asset Management’s Citius Pharmaceuticals CTXR Stock Holding History

Princeton Global Asset Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$97	Hold	160	–	–	﹤0.01%	828
2026 Q1	$144	Hold	160	–	–	﹤0.01%	823
2025 Q4	$124	Hold	160	–	–	﹤0.01%	824
2025 Q3	$198	Hold	160	–	–	﹤0.01%	753
2025 Q2	$254	Hold	160	–	–	﹤0.01%	745
2025 Q1	$238	Hold	160	–	–	﹤0.01%	589
2024 Q4	$640	Hold	160	–	–	﹤0.01%	633
2024 Q3	$2K	Hold	160	–	–	﹤0.01%	607
2024 Q2	$2.33K	Hold	160	–	–	﹤0.01%	587
2024 Q1	$3.59K	Hold	160	–	–	﹤0.01%	506
2023 Q4	$3.03K	Hold	160	–	–	﹤0.01%	534
2023 Q3	$2.74K	Hold	160	–	–	﹤0.01%	501
2023 Q2	$4.8K	Hold	160	–	–	﹤0.01%	472
2023 Q1	$4.68K	Buy	+160	New	+$4.61K	﹤0.01%	480

Other funds holding CTXR

AAG

Asset Advisory Group Kinnelon, New Jersey $229M AUM

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Princeton Global Asset Management's CTXR Position: Q2 2026 in Review

Princeton Global Asset Management held its Citius Pharmaceuticals (CTXR) position steady in Q2 2026 at 160 shares worth $97. The position accounts for ﹤0.01% of the portfolio, ranked #828.

Princeton Global Asset Management first reported a position in CTXR in Q1 2023 and has held it in 14 quarters since. The position peaked at $4.8K in Q2 2023. 3 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

Princeton Global Asset Management held 160 shares of Citius Pharmaceuticals worth $97 as of Q2 2026.
Princeton Global Asset Management left its Citius Pharmaceuticals share count unchanged in Q2 2026.
Citius Pharmaceuticals made up ﹤0.01% of Princeton Global Asset Management's portfolio in Q2 2026, its #828 holding.
Princeton Global Asset Management first reported a position in Citius Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
Princeton Global Asset Management's Citius Pharmaceuticals position peaked at $4.8K in Q2 2023.
3 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.